The GLP is committed to full transparency. Download and review our Annual Report.

Going hostile with $2.6 billion Human Genome offer

| | May 15, 2012

GlaxoSmithKline will take its $2.6 billion bid for long-time partner Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group’s board. The decision to go hostile with the $13-a-share cash tender offer sets up GSK for a potentially lengthy battle with those Human Genome investors who believe it is not offering enough.

View the original article here: GSK goes hostile with $2.6 billion Human Genome offer

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend